ABSTRACT: Protease inhibitor resistance still poses one of the greatest challenges in treating HIV. To better design inhibitors able to target resistant proteases, a deeper understanding is needed of the effects of accumulating mutations and the contributions of active-and nonactive-site mutations to the resistance. We have engineered a series of variants containing the nonactive-site mutations M46I and I54V and the active-site mutation I84V. These mutations were added to a protease clone (V6) isolated from a pediatric patient on ritonavir therapy. This variant possessed the ritonavir-resistance-associated mutations in the active-site (V32I and V82A) and nonactive-site mutations (K20R, L33F, M36I, L63P, A71V, and L90M). The I84V mutation had the greatest effect on decreasing catalytic efficiency, 10-fold when compared to the pretherapy clone LAI. The decrease in catalytic efficiency was partially recovered by the addition of mutations M46I and I54V. The M46I and I54V were just as effective at decreasing inhibitor binding as the I84V mutation when compared to V6 and LAI. The V6 54/84 variant showed over 1000-fold decrease in inhibitor-binding strength to ritonavir, indinavir, and nelfinavir when compared to LAI and V6. Crystalstructure analysis of the V6 54/84 variant bound to ritonavir and indinavir shows structural changes in the 80's loops and active site, which lead to an enlarged binding cavity when compared to pretherapy structures in the Protein Data Bank. Structural changes are also seen in the 10's and 30's loops, which suggest possible changes in the dynamics of flap opening and closing.
The development of resistance to protease inhibitors (PI) 1 during treatment of infection by the Human Immunodeficiency Virus (HIV) still poses one of the greatest challenges in the struggle to limit the virus replicative capacity. After initiation of therapy with single or multiple protease inhibitors, resistance mutations in the protease can appear within weeks. Under a constant drug selection pressure, resistant mutations continue to accumulate. It is clear that there is a correlation between the number of resistance mutations and the level of resistance and cross resistance to multiple protease inhibitors. It is of great interest to understand the level of contributions made by active-and nonactive-site mutations to the development of a high level of resistance (1) (2) (3) (4) (5) (6) . The HIV protease is a symmetric dimer composed of two 99-residue polypeptides ( Figure 1 ). The dimerization region comprises the floor of the active site, which includes two catalytic aspartic acids (Asp25), one provided by each polypeptide. Unlike the human aspartic proteases that have one flap, two flaps completely cap the active site of the HIV protease. A more detailed description of HIV-1 protease structure, inhibitor binding, and resistance can be found in reviews by Wlodawer and Gustchina, Tomasselli and Heinrikson, and Dunn (7) (8) (9) .
In this study, we analyze the effect of adding the nonactive-site mutations M46I and I54V and the active-site mutation I84V to a post-ritonavir therapy protease variant (V6) already containing PI-resistance-associated mutations FIGURE 1: HIV-1 protease homodimer consists of two chains, A (white) and B (green). Residue changes in the V6 variant are marked by orange spheres. Mutations engineered onto the V6 variant background are shown in blue. The catalytic aspartic acids from each chain (D25 and D25′) and the inhibitor indinavir are shown as red stick models in the active site. This figure was created using the V6 54/84 -indinavir structure.
at residues 20, 32, 33, 36, 63, 71, 82 , and 90 ( Figure 1 and Table 1 ). Mutated residues in variant V6 compared to LAI (wild type) are shown in Table 1 . Molla et al. showed that mutations in the protease gene during ritonavir therapy occurred in an ordered fashion (10) . Mutation V82A was associated with the initial loss of antiviral activity. Subsequently, the following mutations were observed most frequently: I54V, A71V, and M36I. Later, proteases containing mutations I84V, K20R, M46I, L33F, and L90M appeared. The mutation I84V has been seen in patients receiving ritonavir, indinavir, amprenavir, and saquinavir therapy and tends to develop in combination with L90M to provided a high level of clinical resistance (11, 12) . Mutations at position 54, I54L/T/M, and most frequently I54V, have been reported in response to ritonavir, indinavir, amprenavir, saquinavir, and lopinavir (10, 13, 14) . The mutation M46I has been observed in response to therapy with ritonavir, amprenavir, indinavir, and nelfinavir (10, 13, 14) .
This study analyzed the effect of accumulating two commonly observed nonactive-site mutations (M46I and I54V) on inhibitor binding and substrate catalysis. It also aimed to study the effect of adding the active-site mutation I84V to address the level of biochemical resistance, cross resistance, and individual contribution to resistance between active-and nonactive-site mutations. Finally, we addressed the structural changes in the most resistant protease by determining its crystal structure in complex with ritonavir and indinavir. These experiments showed the level of resistance and cross resistance incurred by a large number of mutations commonly seen in response to ritonavir therapy.
EXPERIMENTAL PROCEDURES

Mutagenesis and Expression of Protease.
A complete description of the cloning, expression, and purification procedures can be found in Ido et al. and Goodenow et al. (15, 16) . In brief, the HIV-1 PR DNA for all of the HIV LAI variants was subcloned into the pET23a expression vector (Novagen) (17) . The construct was transformed into the Escherichia coli strain BL21 Star DE3 PlysS from Invitrogen. All other constructs were subcloned into the pET11a vector (Novagen) and transformed into the E. coli strain JM109 DE3. The introduction of all mutations onto the V6 background was done using the QuikChange Mutagenesis Kit from Stratagene. Protease expression was initiated when OD 600 reached 0.6 by addition of 1 mM IPTG to a culture grown at 37°C in M9 media (6.8 g of Na 2 -HPO 4 , 3 g of KH 2 PO 4 , 0.5 g of NaCl, 1 g of NH 4 SO 4 , and 5 g of Casamino Acids were autoclaved together in 987 mL of H 2 O, and then 1 mL of 0.1 M CaCl 2 , 2 mL of 1.0 M MgSO 4 , 10 mL of 20% glucose, and 50 µg/L of ampicillin were added). After 3 h, cells were harvested by centrifugation at 16000g for 5 min and resuspended in TN buffer (0.05 M Tris, 0.15 M NaCl, and 0.001 M MgCl 2 at pH 7.4). Inclusion bodies containing the protease were isolated by centrifugation through a 27% sucrose cushion. The inclusion bodies were solubilized in 8 M urea, and the protease was refolded by dialysis against 0.05 M sodium phosphate buffer (0.05 M Na 2 HPO 4 , 0.005 M EDTA, 0.3 M NaCl, and 0.001 M dTT at pH 7.3). The protease was purified through ammonium sulfate precipitation and gel-filtration chromatography using a Superdex 75 16/60 column from Amersham Pharmacia, attached to an FPLC LCC 500 Plus, also from Amersham Pharmacia. The protease was eluted using potassium phosphate buffer (50 mM K 2 HPO 4 , 2 mM EDTA, 150 mM NaCl, 2 mM dTT, 5% glycerol, and 5% 2-propanol at pH 7.3).
Protease ActiVity and Inhibitor Constants. The MichaelisMenten constants k cat , K m , and k cat /K m and K i values were determined for each variant as previously described (18) . The chromogenic substrate K-A-R-V-L*Nph-E-A-nL-G, which mimics the CA-p2 cleavage site, was used to determine the catalytic activity of each variant at 37°C in sodium acetate buffer (0.05 M NaOAc, 0.15 M NaCl, 0.002 M EDTA, and 0.001 M dTT at pH 4.7). K i values for all inhibitors were determined under the same conditions. Cleavage of the substrate was monitored using a Hewlett-Packard 8452A spectrophotometer equipped with a 7-cell sample handling system as described by Dunn et al. (19) . The inhibition constants K i were determined by monitoring the inhibition of hydrolysis of the chromogenic substrate as described by Bhatt et al. (20) .
Crystallization of Protein-Inhibitor Complexes. Inhibitors were dissolved in 100% DMSO and mixed with the protein in a molar ratio of 10:1. The enzyme concentration used was 3 mg/mL in 50 mM sodium acetate at pH 4.7. The final concentration of DMSO was 10%. The inhibitor-protein mixture was combined with the reservoir solution in a 1:1 (v/v) ratio to set up hanging drops of 4 µL at room temperature. The reservoir solution contained 1.5 M ammonium sulfate and 20 mM sodium acetate at pH 6.0 and 4.5 for the ritonavir and indinavir complexes, respectively. Rod-shaped crystals appeared overnight and grew to full size in a week.
Data Collection, Structure Determination, and Refinement. X-ray diffraction images for the ritonavir and indinavir complexes were collected at room temperature and 100°K, respectively, using an R-AXIS IV++ image plate system with Osmic mirrors and a Riguku HU-H3R Cu rotating anode operating at 50 kV and 100 mA. Each data set was collected from a single crystal. The indinavir complex crystal was dipped in a cryoprotectant solution (30% glycerol in reservoir solution) prior to data collection. The data were indexed, scaled, and reduced using DENZO and SCALEPACK (21) . Both complexes were crystallized in the hexagonal P6 1 space group.
Initial phases were calculated by the molecular replacement method, employing the coordinates of the HIV-1 proteaseritonavir structure (PDB entry 1HXW) as a search model after removing the inhibitor and water molecules. Standard methods of structure refinement were then employed using programs in CNS Suite (22) . Difference electron density maps with coefficients 2F o -F c and F o -F c were used to guide manual fitting of the models in the molecular graphics program O7 (23) . Amino acid differences were observed in the electron density (compared to 1HXW) and were replaced according to the V6 54/84 sequence. Water molecules were added into the model using a density set at 2σ. In the final stage of the refinement, the inhibitors were modeled into the active site. During model building and refinement, 5% of the data was reserved for cross validation to monitor the refinement progress. Details of the data collection and refinement statistics are shown in Table 2 . The atomic coordinates have been deposited in the Protein Data Bank: 1SGU and 1SH9 for indinavir and ritonavir structures, respectively. Figures 1-4 and 6-8 were generated using the PyMOL Molecular Graphics System (24) . The separated surfaces were generated using the Molcad module in Sybyl 6.9 (25, 26) . The separated surfaces were calculated between the van der Waals surfaces of all atoms and are defined by a set of points halfway between the shortest distance separating the inhibitor and the enzyme. Grid width was set to 0.4 Å, and virtual sphere radius was set to 4.0 Å. Structural alignments of backbone atoms were done using the Biopolymer module in Sybyl 6.9. , using a synthetic substrate that mimics the CA-p2 site of Gag (Table 3 ). The V6, V6 46 , V6 54 , and V6 84 variants all experienced a decrease in k cat /K m of 2-, 2-, 3-, and 10-fold, respectively, when compared to LAI ( Table  2 ). Variants V6 46/84 , V6 54/84 , and V6
RESULTS
Kinetic
46/54/84 showed a decrease in k cat /K m of 5-, 8-, and 6-fold, respectively, when compared to LAI. Dissociation Constants. The K i values for the wild-type enzyme with all of the inhibitors tested were subnanomolar to low nanomolar in agreement with other studies (Table 4 ) (5, (27) (28) (29) . The V6 variant showed a large decrease in susceptibility to ritonavir. This was not surprising because this variant was isolated from a pediatric patient on ritonavir therapy. A 43-and 22-fold increase in K i was also seen for nelfinavir and indinavir, respectively. The V6 variant only offered a small level of biochemical cross resistance to AG1776, when compared to indinavir, nefinavir, and ritonavir, even though V6 contains various mutations commonly seen in response to multiple inhibitors, specifically the key mutations V82A and L90M (10) (11) (12) (13) (30) (31) (32) (33) .
The addition of mutation M46I, which is seen in response to each inhibitor tested, decreased the potency of all of the inhibitors, with indinavir showing the lowest potency with a 630-fold increase in the K i value followed by nelfinavir (96-fold), ritonavir (90-fold), and AG1776 (23-fold). It should be noted that AG1776 still bound with a subnanomolar dissociation constant. The addition of mutation I54V to V6 had the greatest effect on the binding of ritonavir and indinavir with a 155-and 127-fold decrease in affinity, respectively. The V6 54 variant showed a lesser effect on nelfinavir and AG1776 with an 18-and 8-fold increase in the K i value, respectively. Variant V6 84 showed a greater decrease in inhibitor susceptibility (235-fold) to ritonavir than did V6 46 and V6
54
. To our surprise, the addition of mutation I84V decreased the binding affinity of indinavir to a lesser extent than M46I and I54V, 540-and 34-fold less, respectively, and the affinity of nelfinavir was 96-fold less than that of the mutation M46I. Of the single mutations added to V6, I84V showed the greatest effect on the binding of AG1776 with a 25-fold increase in the K i value.
The double mutant V6 46/84 further decreased the binding of ritonavir when compared to V6, V6 46 , V6 54 , and V6
84 from 250-to 450-fold. Although this variant showed a decrease in susceptibility to indinavir when compared to V6 (20-fold), a greater decrease was seen for variants V6 46 (630-fold) and V 54 (130-fold). Addition of mutations M46I and I84V to V6 lessened the affinity of nelfinavir by 19-fold when compared to that of LAI but was less than what was seen with the single mutants. Variant V6 46/84 also showed a large decrease in susceptibility to AG1776 (104-fold) when compared to any of the variants discussed thus far. Although a large fold decrease in inhibitor susceptibility was seen with previously 
where Ii(hkl) is the ith observation of the intensity of a reflection with indices h, k, and l and 〈I(hkl)〉 is the average intensity of all symmetry equivalent measurements of that reflections. b Rwork ) ∑hkl(Fobs(hkl) -Fcalc(hkl))/ Fobs(hkl) × 100, where Fobs(hkl) and Fcalc(hkl) are the observed and calculated structure factor amplitudes, respectively. c Rfree was calculated using 5% of data excluded during the refinement process. In parenthesis is the highest resoltuion shell. 54/84 , which showed the greatest decrease in inhibitor-binding strength to all inhibitors tested, in complex with ritonavir and indinavir, and solved the structures at 2.5 Å and 1.9 Å resolution, respectively ( Figure 2 ). The structural overlaps of the wildtype ritonavir (PDB 1HXW) and indinavir (PDB 1HSQ) complexes and V6 54/84 in complex with ritonavir and indinavir are shown in Figure 3 . Sequence differences between the wild-type structure proteases and LAI are shown in Table  1 .
V6 54/84 -IndinaVir Structure. Structural alignment of CR atoms of V6 54/84 -indinavir and the wild-type proteaseindinavir structure shows large structural changes in the 10's (residues 14-20), 30's (residues 30-40), 60's (residues 63-73), and 80's (residue 78-85) loops ( Figure 3A) . The average distances between equivalent CR atoms over the 99 residues in chains A and B of the two structures are 0.57 and 0.56 Å, respectively. The average CR separation between the two structures and the residue number at peak distance for the loops listed above are shown in Table 5 . Although the loops in both chains of the homodimer show an increase in the separation of equivalent CR atoms, the magnitude is asymmetric. This is most likely an effect from the asymmetric inhibitor bound in the active site.
The V6 54/84 variant contains three mutations in the active site, V32I, V82A, and I84V, and occupies the S2/S2′ (32) and S1/S1′ (82 and 84) pockets. These pockets interact with the core of the inhibitor. The interaction of indinavir with the active-site residues of both the wild-type and V6 54/84 enzyme was compared using LIGPLOT (57) . Shown in Figure 4 are the hydrophobic interactions with residues 32, 82, and 84 and all hydrogen bonds between the inhibitor and the enzyme. Indinavir makes no hydrophobic contact with residues Ile32(A), Ala82(A), and Val84(A) and (B) in the V6 54/84 structure. There are two hydrophobic points of contact made between Ile32(B) and the aminoindanol in the P2′ position of indinavir. Three hydrophobic points of contact are made between A82(B) and the P1′ phenyl ring of indinavir. When compared to the wild-type structure, this equates to a loss of four hydrophobic points of contact encompassing residues 32(A), 82(A), and 84(B). Indinavir establishes four direct and four water-mediated hydrogen bonds with active-site residues. When compared to the wildtype structure, one direct and one water-mediated hydrogen bond are lost. Generation of a separated surface showed a volume of 1266 Å 3 and an area of 1001 Å 2 of interaction between the enzyme and inhibitor ( Figure 5A ). When compared to the wild-type structure there is an increase in the volume and area of 230 Å 3 and 131 Å 2 , respectively, in the separated surface of interaction. The increase in the volume and area can be mapped to the S1′, S2, and S2′ sites. -ritonavir structure also shows structural changes in the 10's, 30's, 60's, and 80's loops when compared to the wild-type complex of ritonavir ( Figure 3B ). The average distances between equivalent CR atoms and the residue number at peak distance for the loops listed above are shown in Table 5 . The average CR separations between the two structures over the 99 residues in chains A and B are 0.64 and 0.52 Å, respectively. As with the indinavir structure, there is an asymmetry in the CR distance variations in each loop between the two chains. Again, this is most likely an effect of the asymmetric inhibitor bound in the active site.
The interactions of ritonavir with the active-site residues 32, 82, and 84 of the V6 54/84 enzyme were compared using LIGPLOT. Shown in Figure 4 are hydrophobic interactions and all hydrogen bonds between the inhibitor and the enzyme. Ritonavir in the V6 54/84 variant makes no hydrophobic contacts with residues Ala82(A) and (B) and Val84-(A) and (B). Two hydrophobic points of contact are made between the Ile32(A) residue and the Val side chain of ritonavir in the S2 pocket. One hydrophobic point of contact is made between the Ile32(B) residue and the methoxycarbonyl group of ritonavir occupying the S2′ pocket. When compared to the wild-type structure, there is a total loss of six hydrophobic points of contact with residues 82(A) and (B) and 84(A). Ritonavir establishes four direct and one water-mediated hydrogen bond with active-site residues. When compared to the 1HXW structure, two direct and one water-mediated hydrogen bond are lost. Generation of a separated surface showed a volume of 1341 Å 3 and an area of 985 Å 2 of interaction between the enzyme and inhibitor ( Figure 5B) . When compared to the wild-type structure, there FIGURE 3: Ribbon representation of a CR overlap of (A) 1HSG (white) and V6 54/84 -indinavir (beige) and (B) 1HXW (white) and V6 54/84 -ritonavir (beige) structures. The 10's, 30's, 60's, and 80's loops are colored blue, aqua, red, and green, respectively, in the mutant structures. Below each structure is a bar-graph representation of the CR distances between the wild-type structure and V6 54/84 for chain A (blue) and chain B (red). These graphs were created by subtracting the average CR separation for each chain from the CR distance of each residue in the corresponding chain. is an increase in the volume and area of 234 Å 3 and 114 Å 2 , respectively, in the separated surface of interaction. The increase in the volume and area can be mapped to the S1′, S2, S2′, and S3 sites.
DISCUSSION
The initial resistant variant on which we based our study, V6, was isolated from a pediatric patient while on ritonavir therapy and contains various mutations commonly seen in response to ritonavir (Table 1) . We then added mutations in the flaps (M46I and I54V) and active site (I84V) to assess the effect of accumulating nonactive-and active-site mutations. We analyzed the catalytic efficiency of all variants using a chromogenic substrate that mimics the CA-p2 cleavage site of Gag-Pol. Processing at this site has been shown to be a key regulatory event in the ordered cleavage of Gag-Pol generating mature infectious viruses (34, 35) . The V6 variant when compared to LAI shows a 50% decrease in catalytic efficiency (k cat /K m ) mainly because of a 3-fold increase in K m . Chen et al. reported a mutant protease carrying mutations M46I/L63P, which was catalytically more efficient than wild-type enzyme, while a variant carrying mutations V82T/I84V had very poor catalytic activity (36) . This would suggest that mutations at positions 46 and 63 should compensate for a decrease in catalytic efficiency because of mutations at positions 82 and 84. The variants we analyzed in this study contain, in addition to M46I and L63P, M36I and A71V mutations also thought to compensate for catalytically deleterious mutations (37, 38) . The activesite mutation I84V was the only single mutation when added to V6 that caused a significant decrease in k cat /K m (10-fold). The addition of mutations M46I and I54V to V6 also decreased the catalytic efficiency of the protease when compared to V6 by 2-and 3-fold, respectively. Addition of mutations M46I and/or I54V to the V6 84 variant improved catalytic activity when compared to that of V6 84 by up to 5-fold for variant V6 46 , it appears that the M46I mutation provides a greater improvement in catalytic efficiency than the I54V substitution (39) . Surprisingly, the addition of the mutations M46I and/or I54V did not improve the catalytic efficiency of the V6 variant, which contains the active-site mutations V32I and V82A and the nonactive-site mutations L63P, M36I, and A71V. Protease sequences from additional viruses isolated at 28 and 40 weeks show the presence of the M46I or I54V mutations (data not shown). This suggests that the decrease in catalytic efficiency offered by the M46I and I54V mutations is acceptable for virus replication and is selected for decreasing the inhibitor binding. Also, improvements in catalytic activity are a product not of individual residues but of residue combinations.
We analyzed the inhibition of all variants with the three clinically used inhibitors ritonavir, indinavir, and nelfinavir. We also tested the inhibition of these variants by the inhibitor AG1776, which is an allophenylnorstatine-based lead compound that has shown strong inhibition of HIV-1-resistant variants (40) . The V6 variant showed a 42-fold decrease in inhibition by ritonavir. This was expected because V6 was isolated from a patient receiving ritonavir. The V6 variant also showed cross resistance to nelfinavir and indinavir but maintained susceptibility to AG1776. V6 contains six mutations (K20R, V32I, M36I, L63P, A71V, and V82A) commonly seen in response to indinavir therapy, which highly overlap with mutations commonly seen to ritonavir. V6 carries three mutations (M36I, A71V, and V82A) commonly seen in response to nelfinavir therapy. We previously demonstrated the cooperative effect of M36I and A71V with the active-site mutation D30N to provide for the high level of resistance to nelfinavir (18) . The combination of mutations in V6 does not provide for a high level of resistance to AG1776. The most frequently seen mutations in vitro in response to AG1776 include M46I, I47V, and I84V and less frequently, V32I and V82I (41) . The susceptibility of V6 to inhibition by AG1776 might be due to the presence of only a single low occurring specific mutation, V32I, seen in vitro in response to this inhibitor.
The addition of mutation M46I (V6 46 ) had its greatest effect on the binding of indinavir with a 630-fold increase in K i when compared to that of LAI and 28-fold for V6. The V6 46 enzyme carries two major mutations (V82A and M46I) commonly seen in response to indinavir. The M46I mutation also decreased the binding affinity for the three other inhibitors tested but not to the same degree. The M46I mutation is not considered a major mutation for ritonavir or nelfinavir and caused only a ∼2-fold increase in the K i value for both inhibitors when compared to that of V6. The M46I mutation is consider a major mutation for AG1776 and caused a ∼10-fold increase in K i for this inhibitor. It should be noted that AG1776 still binds with a subnanomolar K i value. The I54V mutation is not considered a major mutation against any of the inhibitors tested, and it is not a mutation associated with nelfinavir resistance. This mutation is, however, highly associated with the V82A mutation, which has been associated with resistance to all clinically used inhibitors (42, 43) . The addition of mutation I54V (V6 54 ) generated an enzyme less susceptible to ritonavir (∼4-fold), indinavir (∼80-fold), and AG1776 (∼5-fold) and an enzyme more susceptible to nelfinavir (∼2-fold) when compared to that of V6.
Both the M46 and I54 residues are found in the flaps of the protease. Ohtaka et al. previously demonstrated cooperative interactions between M46I and I54V and the active-site V82A and I84V mutations to provide for a high level of cross resistance (44) . The M46 residue occupies a hydrophobic grove occupied by residues Lys55 and Phe53 in the juxtaposed flap strand (Figure 6 ). The I54V mutation sits in a hydrophobic pocket formed by residues Pro79, Ile47, and Val56 in the same chain and residue Ile50 in the flap of the opposite chain. It is clear that residue Ile54 is involved in stabilizing the closed conformation of the flaps and would play a role in the dynamics of flap opening and closing. The M46I mutation juxtaposed to residue 54 and interacting with the residues on either side of 54 is potentially contributing to changes in the interactions between residue 54 and the surrounding residues previously discussed. Examination of the structure (PDB 1C6Y) of a complex of an HIV-1 protease, containing nine mutations including M46I and I54V, with indinavir shows a major change in the position of the 80's loop of chain B but little difference in the closed conformation of the flaps when compared to that of the wild type (45) . The structure of variant V6 54/84 in complex with indinavir and ritonavir also shows changes in the conformation of the 80's loops and little change in the closed conformation of the flaps. This suggests that the effects of mutations M46I and I54V are not affecting the final bound conformation but might be affecting the mechanics of the flaps opening and closing or the stability of the opened or closed conformation.
The addition of the active-site mutation I84V to the V6 variant was not on average as deleterious as adding the nonactive-site mutations M46I or I54V. Combination of I54V with I84V generated the most inhibition insusceptible enzyme (V6 54/84 ) having greater than a 1000-fold increase in K i to all three clinically used inhibitors tested and greater than 450-fold increase for that of AG1776. The variant carrying the triple mutation combination showed the second highest decrease in susceptibility to all of the inhibitors tested but showed higher catalytic activity than the V6 54/84 and V6 84 variants. The accumulation of these mutations provides for an enzyme that is highly cross-resistant and maintains sufficient catalytic activity for virus viability, >5% of wildtype activity (46) (47) (48) .
The inhibitor AG1776 shows a large fold increase in K i to the double and triple mutants when compared to that of the wild type, but when compared to the clinically used inhibitors, it shows an up to 450-fold greater potency. A recent paper by Vega et al. characterizing AG1776 (also know as KNI-764 and JE-2147) by calorimetry and X-ray crystallography shows that its ability to inhibit resistant variants is a product of enthalpy/entropy compensation and structural adaptability (49) .
The crystal structure of V6 54/84 in complex with indinavir and ritonavir shows significant structural changes to the regions containing the described mutations compared to the equivalent areas in the wild-type structures (Figure 3) . In both structures, changes in the conformation of the 80's loops are seen. The 30's and 80's loops have previously been shown to affect substrate specificity (45, 50, 51) . Unlike the structure of a mutant protease complexed with indinavir reported by Munshi et al., where the 80′ loop in chain B moves away from the active site and the P3 group of the inhibitor adopts an alternate conformation, in our structure of ritonavir and indinavir, the 80's loops have moved closer to the active site and the inhibitors display a similar binding mode to that of the wild-type structure. Although the 80's loops have moved closer to the inhibitor, analysis of the active site shows an enlarged binding cleft ( Figure 5 ). The V82A and I84V mutations create expanded S1-S3 and S1′-S3′ pockets (Figures 4 and 5) . Unexpectedly, the V32I mutation also created larger S2 and S2′ pockets. The increase in surface area separating the interface between the inhibitor and the enzyme predicts a decrease in the level of interactions between them. A comparison of the wild-type and V6 54/84 structures shows a loss of hydrophobic contact with residues 32, 82, and 84, in both chains and a loss of hydrogen-bonding interactions (Figure 4) . Instability in the bound inhibitor can also be seen in the P3 group of both complexes, which is defined by poor density (Figure 2 ). Residue 82 is located between the S1 and S3 subsites and can interact with both the P1 and P3 groups of the inhibitors. Residue 82 and 8 sandwich the P3 thiazolyl group of ritonavir (Figure 2 ). The instability of the P3 group is also reflected by the instability in the position of residue 8.
From our kinetic studies, it is clear that the nonactive-site mutations M46I and I54V provide for a high level of inhibitor resistance and cross resistance. Analyses of the regions containing the nonactive-site mutations found in our structures show regions of high variability when compared to the wild-type structures. The highest variability is seen in the 10's and 30's loops (Figure 3) . The 30's loop contains the nonactive-site mutations L33F and M36I. The 10's loop contains the mutation K20R. Residue 20 is found juxtaposed to residues 33 and 36. The structural changes seen in these loops can be attributed to these mutations. A hydrogenbonding network that is not present in the wild-type structure is established between the two strands ( Figure 7) . The Lys20 establishes hydrogen bonds with the carboxyl oxygen of residues Glu35 and Leu19 in both chains in both structures. Hydrogen bonds are found between the O and N of Gln18 and the amine and carboxyl oxygen, respectively, of Ser37 in both structures. The orientation of the O and NH 2 of Gln18 in both chains was based on the potential for hydrogen bonding.
We previously postulated the effects of mutations in this region to affect the dynamics of flap opening and closing (18) . The presence of Phe33, Ileu25, and the R-RC of Lys20 form a highly hydrophobic pocket into which Ile36 fits, allowing the loops to come closer, an average of 2.9 and 3.1 Å for chain A and B, respectively, for both structures and allowing the formation of the hydrogen-bonding network discussed above. It is apparent that the structural changes found between the 30's loop and the 10's loops are pinching that region of the protease. A CR carbon overlap of the unbound (PDB 3HVP) and wild-type and V6 54/84 -bound structures also show the greatest CR distance differences to map to the flaps (residues 45-55) and the 10's, 30's, and 80's loops (Figure 8 ). The presence of mutation I54V changes the interactions that occur between the flaps, the 80's loops, and the opposite flap. The M46I mutation, juxtaposed to residue 54, may function to stabilize the position of residue 54 by interacting with residues 53 and 55. The I84V along with mutations V82A and V32I further destabilizes the core of the inhibitor, which is also involved in two water-mediated hydrogen bonds with the flaps.
We postulate that the effects on inhibitor binding that we see because of the M46I, I54V, and I84V mutations are a result of changes in the interactions between the active-site residues and the inhibitor but, to a greater extent, are a result of changes in the opening and closing dynamics of the flaps caused by the nonactive-site mutations. Work done by other laboratories has shown that changes in the binding affinities of the inhibitors are due to a decrease of k on and an increase of k off rates or an increase of k off rates (52, 53) . This would be consistent with an inability to form stable interactions with the flaps. We postulate that changes in the dynamics of the flaps opening and closing would have a greater effect on the stable binding of rigid inhibitors than the transient binding of flexible substrates. We propose that the interactions coordinated by residue 54 with the 80's loops, the opposite strand of the flaps, and residue 50 of the opposite chain flap are altered by the M46I and I54V mutations and that along with structural changes in the 30's loops, when compared to the unbound structure, they function to destabilize the flaps promoting the open conformation of the protease.
After two decades of intense research around the world, HIV is still a major therapeutic challenge. New drugs for HIV targeting both reverse transcriptase and protease have given those living with the disease hope for the future. Still, therapy is life-long and laboring because of the ability of HIV to quickly acquire resistant mutations, leading to viruses that are cross-resistant to various protease inhibitors. With the presence of these mutations in therapy-naive patients and in the transmission of HIV-1-resistant variants at the time of infection, it has also become clear that a better understanding of these variations is required for initial and ongoing treatment decisions (54) (55) (56) . Our study shows that the accumulation of commonly seen resistant mutations to one inhibitor (ritonavir) will provide for a sufficiently catalytically active protease for virus viability, while providing a large degree of cross resistance. Structural analysis of the most resistance protease in this study shows large structural changes in and away from the active site, suggesting destabilization of the protease closed conformation. Although our in vitro analysis is not without its limitations, it should prove useful in the design of new and continuing therapy.
